XML 85 R27.htm IDEA: XBRL DOCUMENT v3.24.3
2023 GXII TRANSACTION (Tables)
12 Months Ended
Jun. 30, 2024
Business Combination and Asset Acquisition [Abstract]  
The following table summarizes the elements of the GXII Transaction allocated to the Consolidated Statements of Operations and Comprehensive Loss for the year ended June 30, 2023:

After the distribution of funds to GXII redeeming shareholders and prior to paying transaction costs incurred by GXII, $15,676 became available to the Company. The following table summarizes the elements of the GXII Transaction allocated to the Consolidated Statements of Operations and Comprehensive Loss for the year ended June 30, 2023:

 

     Amount 
Gross cash proceeds, net of transaction costs incurred by GXII  $2,168 
Less:     
Cash costs associated with the 2023 Transactions:     
Net liabilities assumed   392 
Yorkville Equity Facility Financing Agreement – cash costs   1,996 
Transaction costs expensed   6,715 
Non-cash costs associated with the 2023 Transactions:     
Private Warrants assumed at fair value   2,987 
Earnout Shares assumed at fair value   13,195 
Yorkville Equity Facility Financing Agreement – shares issued   650 
 Total transaction related losses incurred  $23,767 
The number of Common Shares issued and outstanding immediately following the consummation of the 2023 Transactions were as follows

The number of Common Shares issued and outstanding immediately following the consummation of the 2023 Transactions were as follows:

 

   Common Shares   Percentage 
Legacy NioCorp Shareholders   28,246,621    93.90%
Former GXII Class A Shareholders(1)   1,753,821    5.83%
Other(2)   81,213    0.27%
Total Common Shares Outstanding Upon Completion of 2023 Transactions   30,081,655    100%

 

  (1) Includes 83,770 Common Shares issued to BTIG, LLC in exchange for Class A shares of GXII that it received as partial payment for advisory services.
  (2) Represents Commitment Shares (as defined in Note 11d) issued under the Yorkville Equity Facility Financing Agreement.